Zydus Lifesciences gets US FDA nod for platelet-boosting drug Eltrombopag

• Zydus Lifesciences received final US FDA approval for Eltrombopag Tablets on January 15.
• The drug is approved in strengths of 12.5 mg, 25 mg, 50 mg, and 75 mg.
• Eltrombopag treats thrombocytopenia (low platelet count) by stimulating bone marrow to produce more platelets.
• The tablets will be manufactured at Zydus' SEZ formulation facility in Ahmedabad.
• Annual sales of Eltrombopag in the US market are $1,262.5 million (IQVIA MAT, Nov 2025).

Why It Matters: Zydus Lifesciences secures US FDA approval for its platelet-boosting drug Eltrombopag, enhancing its market presence.